Selected publications from leading medical journals — concisely summarised and put into context for trial practice. Updated three times a week.
Last updated:
Nature Medicine
Immunotherapy: real-world data reveal toxicity differences that trials did not show
A large-scale analysis of real-world data shows differences between ethnic groups in the occurrence of immune-related adverse events during cancer immunotherapy. These differences were not visible in the original clinical trials.
What it means for trial practice: It underlines the importance of representative trial populations — access barriers can systematically exclude certain groups from trials.
Original title: Hidden race disparities in cancer treatment toxicity
Personalised cancer vaccines in ovarian cancer: phase 1 trial shows feasibility
In a phase 1 trial, patients with high-grade serous ovarian cancer received personalised neoantigen-targeting vaccines combined with PD-1 blockade. The approach proved feasible.
What it means for trial practice: Individualised therapies place high demands on sample handling, logistics and scheduling — operational delivery decides trial success here.
Original title: Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial
Cold or room temperature? Randomised trial compares platelets in cardiac surgery
A randomised non-inferiority trial investigates whether platelets cold-stored for up to 21 days are as effective and safe as room-temperature platelets stored for 5 to 7 days in patients with active bleeding during cardiac surgery.
What it means for trial practice: The trial shows how directly storage conditions and shelf life determine feasibility — a core topic of temperature-controlled trial logistics.
Original title: Cold and Room-Temperature Platelets in Cardiac Surgery
How much evidence does comparing common treatments require?
A comment discusses the level of evidence needed for trials comparing several established treatment options. The problem is often not a lack of evidence as such, but a lack of robust randomised comparative data.
What it means for trial practice: Pragmatic comparative trials in routine care are gaining importance — and need lean, patient-centred processes to reach enough participants.
Original title: Tailoring levels of evidence in trials comparing common treatments
Hereditary angioedema: oral on-demand therapy relieves attacks faster than placebo
In a multicentre, randomised, double-blind, placebo-controlled phase 3 crossover trial, orally administered deucrictibant led to faster symptom relief than placebo for hereditary angioedema attacks and was generally well tolerated.
What it means for trial practice: On-demand therapies that patients use themselves at home shift trial activity into everyday life — creating new demands on documentation and support.
Original title: Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial
COPD: trial successes with an IL-33 antibody raise hopes for respiratory diseases
The IL-33-targeting antibody tozorakimab reduced flare-ups in patients with COPD in trials. This raises hopes that the mechanism could be used more broadly in pulmonary diseases.
What it means for trial practice: Respiratory trials with often older participants of limited mobility benefit particularly from home visits and continuous support.
Original title: COPD trial wins spur broad respiratory hopes
These summaries are written by VALEA Clinical based on the respective publication and are for information purposes only. They replace neither the original publication nor medical advice. The linked original source is always authoritative; all rights remain with the respective publishers.
Sources: The New England Journal of Medicine, The Lancet, JAMA, The BMJ, Nature Medicine, Nature Reviews Drug Discovery.